Document Type
Original Article
Abstract
Background: The most common molecular subtype of breast cancer worldwide is luminal breast cancer. It has shown a good prognostic profile compared to other types. Despite the immense development of adjuvant treatment in the past years, around 20% of patients with early-stage disease relapse. Aim of the study: To evaluate the relapse pattern in luminal breast cancer and the correlation between luminal types and (AJCC 8th edition). Subject and Methods: A total of 230 luminal breast cancer patients treated at Al-Hussein University Hospital between 2013 and 2018 were analyzed. Patients have been divided into the following groups: luminal A (31%) and B (32.6%), luminal B HER2+ve (18.6%), and luminal UC (17.3%). Results: The median follow-up was 66.7 months, and the relapse rate of luminal breast cancer was 27.8%. Although statistically not significant, luminal A had the lowest relapse rate (19.4%), while luminal B (36%), HER2 positive luminal B (23.2%), and luminal UC (32.5%) (p=0.117). The predominant organ relapse was bone (29.6%) mainly observed in luminal A and B, 35.7% and 32.3% of patients respectively (p=0.048). Luminal Correlation with the AJCC staging system was significant, luminal A was most often observed in early stages with 81.9% presented in Stages I to II (p=0.008). Conclusions: Luminal breast cancer has a wide discrepancy in relapse rate and pattern. Luminal A seems to have the best prognosis for DFS. Ki-67 % and HER2 testing would give a prognostic factor in luminal subcategorization and could be beneficial in the intensification of adjuvant therapy.
Keywords
Breast Cancer, Luminal Type, Adjuvant, Relapse, AJCC
How to Cite This Article
Abdelaziz, Mohamed Ahmed; Ebrahim, Eslam Mohamed; and El-Din Zikry, Mohsen Salah
(2023)
"Evaluation of Pattern of Relapse in Luminal Breast Cancer,"
Al-Azhar International Medical Journal: Vol. 4:
Iss.
3, Article 9.
DOI: https://doi.org/10.58675/2682-339X.1686
